CN104800396A - Anesthetic and preparation method and use method thereof - Google Patents
Anesthetic and preparation method and use method thereof Download PDFInfo
- Publication number
- CN104800396A CN104800396A CN201510210042.2A CN201510210042A CN104800396A CN 104800396 A CN104800396 A CN 104800396A CN 201510210042 A CN201510210042 A CN 201510210042A CN 104800396 A CN104800396 A CN 104800396A
- Authority
- CN
- China
- Prior art keywords
- propofol
- anesthetis
- extract
- powder
- mentholum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention belongs to the technical field of medicines, and particularly discloses an anesthetic. According to the anesthetic, propofol is used as a basic medicament, and a chamomile extract, astragalus powder, mentholum, radix notoginseng powder and a flos daturae extract are used as auxiliary medicaments. The invention further provides a preparation method and a use method of the anesthetic. By adoption of a western and traditional Chinese medicine combined technology, under the condition of keeping the original propofol medicament effect, the pain easing function is enhanced; furthermore, a more serious circulation suppression and breathing suppression effect caused by the propofol is effectively improved; during use, the use amount of a cooperatively used pain killer is reduced, the side effect of the medicament is reduced, and the clinical safety is improved.
Description
Technical field
The invention belongs to medical art, be specifically related to a kind of anesthetis.
Background technology
Propofol (propofol), its chemistry 2,6-diisopropylphenol by name is novel quick, the fugitive intravenous anesthetic of one being commonly used to induction of anesthesia, anesthesia maintenance, ICU critical patient calmness at present clinically.Propofol injection is white isotonic intravenous fluid, and every milliliter, containing Disoprivan 10 milligrams, includes refined soybean oil, refine yolk lecithin, glycerol and water for injection etc. simultaneously.This product is the fugitive intravenous anesthetic of induced by alkyl hydroxybenzene, by activating GABA receptor-chloride complex, plays sedative-hypnotic effect.During clinical dosage, propofol increases chloride conductance, makes the sense of GABA receptor desensitization time heavy dose of, thus suppresses central nervous system, produces calm, hypnotic effect, and it is 1.8 times of penthiobarbital that its anesthesia is tired.Rapid-action, action time is short, and during with 2.5mg/kg intravenous injection, onset time is 30-60 second, holds time about about 10 minutes, revives rapidly.
In current clinical anesthesia application, mostly be single choice propofol and carry out balanced anesthesia, propofol has strong vasodilator and myocardiac inhibition and respiration inhibition effect, often cause comparatively serious cyclic inhibition and respiration inhibition effect, special 5 is more obvious by respiration inhibition during opioid drug, and propofol agent does not have pain relieving performance, need alleviate pain in anaesthesia process with the use of analgesic drug product, cause anesthetic risks and untoward reaction to increase, clinical application range is limited.
Summary of the invention
An object of the present invention is, the defect of balanced anesthesia is carried out for alone propofol, develop a Novel anesthetic, described anesthetis is in the pharmaceutically-active situation of the original propofol of maintenance, improve analgesia function, and the comparatively serious cyclic inhibition effectively improved caused by propofol and respiration inhibition effect, decrease the consumption with the use of analgesic during use, reduce drug side effect, improve clinical safety.
The invention provides a kind of anesthetis, medicine based on propofol, with camomile extract, astragalus membranaceus powder, Mentholum, Radix Notoginseng powder and Flos Daturae extract for ancillary drug, described component is counted with quality proportioning:
Propofol 85 ~ 90%.
Camomile extract 0.5% ~ 2.5%.
Astragalus membranaceus powder 1% ~ 3%.
Mentholum 0.5% ~ 1%.
Radix Notoginseng powder 1% ~ 3%.
Flos Daturae extract 4% ~ 8%.
The invention provides a kind of above-mentioned narcotic preparation method, camomile extract, astragalus membranaceus powder, Mentholum, Radix Notoginseng powder and Flos Daturae extract is specifically comprised the steps: to join respectively in propofol emulsion according to described formula dosage, at room temperature leave standstill after mixing and stirring, use vial to seal up for safekeeping.
Described room temperature is 20 ~ 25 DEG C, and described vial volume is 20mL.
The present invention also provides a kind of above-mentioned narcotic using method, specifically comprises:
Described anesthetis can assist for spinal cord and epidural anesthesia and with conventional premedicant, neuromuscular blocking drug, inhalation anesthetic and analgesic with the use of.
Described anesthetis need dilute rear use, and with 5% glucose intravenous fluid dilution, dilution factor must not more than 1: 5.
Described anesthetis need use target control pump or micro pump to use through intravenous injection.
Described anesthetis adult dosage is 0.5 ~ 1.5mg/kg at induction period, and injection speed controls at 2mg/s, is 2 ~ 6mg/kg/h in maintenance phase.
Described anesthetis pediatric pharmaceuticals amount is 1.0 ~ 2.0mg/kg, and injection speed controls at 2mg/s, is 5 ~ 8mg/kg/h in maintenance phase.
Need with the use of low dose of analgesic when being used for general anesthesia without the need to analgesic with the use of, described anesthetis when described anesthetis is used for Little operation.
In described anesthetic formulations: Flos Daturae, containing alkaloid and atropine, there is narcotic analgesic, effect that spasmolytic is only jerked.Mentholum, has and stimulates skin permeation mucosa, the function of antipruritic, antiinflammatory, pain relieving.Flos Matricariae chamomillae, can alleviate anxiety, anxiety, indignation and fear, people be loosened, has the function of pain relieving simultaneously, can relax myalgia, especially because of the nervous pain caused.Radix Notoginseng, containing Radix Notoginseng total arasaponins, has calm effect to smooth muscle, can loosen overwrought muscle, make it reach sufficient rest, has antiallergic, effect that anti-tic, emesis, anti-inflammatory, antipruritic, rheumatism, antibacterial, spasmolytic, promotion scab.The Radix Astragali, containing flavone and soaping agents composition, have cardiotonic, heart contraction amplitude is increased, output increases, to poisoning or Fatigue failure action of the heart is more obvious, also have and regulate blood pressure function, to blood pressure, there is certain dual regulation, can blood pressure lowering, when blood pressure is down to shock level, the Radix Astragali can make again blood pressure slightly rise and keep stable.
The beneficial effect adopting anesthetis provided by the invention to bring is: the present invention takes the technology of the combination of Chinese and Western medicine, in the pharmaceutically-active situation of the original propofol of maintenance, improve analgesia function, and the comparatively serious cyclic inhibition effectively improved caused by propofol and respiration inhibition effect, decrease during use with the use of the consumption of analgesic, reduce drug side effect, improve clinical safety.
Detailed description of the invention
The invention provides a kind of anesthetis, medicine based on propofol, with camomile extract, astragalus membranaceus powder, Mentholum, Radix Notoginseng powder and Flos Daturae extract for ancillary drug, described component is counted with quality proportioning:
Propofol 85 ~ 90%.
Camomile extract 0.5% ~ 2.5%.
Astragalus membranaceus powder 1% ~ 3%.
Mentholum 0.5% ~ 1%.
Radix Notoginseng powder 1% ~ 3%.
Flos Daturae extract 4% ~ 8%.
The invention provides a kind of above-mentioned narcotic preparation method, camomile extract, astragalus membranaceus powder, Mentholum, Radix Notoginseng powder and Flos Daturae extract is specifically comprised the steps: to join respectively in propofol emulsion according to described formula dosage, at room temperature leave standstill after mixing and stirring, use vial to seal up for safekeeping.
Described room temperature is 20 ~ 25 DEG C, and described vial volume is 20mL.
The present invention also provides a kind of above-mentioned narcotic using method, specifically comprises:
Described anesthetis can be assisted for spinal cord and epidural anesthesia, and with conventional premedicant, neuromuscular blocking drug, inhalation anesthetic and analgesic with the use of; But Little operation does not need to use analgesic, coordinates low dose of analgesic as general anesthesia, decreases the side effect that other analgesic using dosages bring.Suggestion uses target control pump or micro pump to carry out intravenous injection.Described anesthetis also can dilute rear use, and can only dilute with 5% glucose intravenous fluid, dilution factor must not more than 1: 5 (1.5mg/ml).Adult's dosage is 0.5 ~ 1.5mg/kg (induction period), and injection speed controls at 2mg/s (induction period), 2 ~ 6mg/kg/h (maintenance phase); Pediatric pharmaceuticals amount is 1.0 ~ 2.0mg/kg (induction period), and injection speed controls at 2mg/s (induction period), 5 ~ 8mg/kg/h (maintenance phase).
Hereafter will be described further the present invention in conjunction with specific embodiments.It should be noted that the combination of technical characteristic or the technical characteristic described in following embodiment should not be considered to isolated, they can mutually be combined thus be reached better technique effect.
Embodiment 1
Flos Daturae extract 8%, Mentholum 0.7%, camomile extract 2.0%, Radix Notoginseng powder 2.0% and astragalus membranaceus powder 2.3% will be counted with quality proportioning, join respectively and count in the propofol emulsion of 85% with quality proportioning, mix and blend at 20 ~ 25 DEG C of temperature, Homogeneous phase mixing leaves standstill, strict with after national relevant specification process again, use 20mL vial to seal up for safekeeping.
Embodiment 2
To count with quality proportioning; Flos Daturae extract 6%, Mentholum 0.7%, camomile extract 1.5%, Radix Notoginseng powder 1.8%, astragalus membranaceus powder 2.0%, join respectively and count in the propofol emulsion of 88% with quality proportioning, mix and blend at 20 ~ 25 DEG C of temperature, Homogeneous phase mixing leaves standstill, strict with after national relevant specification process again, use 20mL vial to seal up for safekeeping.
Embodiment 3
Flos Daturae extract 4%, Mentholum 0.7%, camomile extract 1.5%, Radix Notoginseng powder 1.5%, astragalus membranaceus powder 2.3% will be counted with quality proportioning, join respectively and count in the propofol emulsion of 90% with quality proportioning, mix and blend at 20 ~ 25 DEG C of temperature, Homogeneous phase mixing leaves standstill, strict with after national relevant specification process again, use 20mL vial to seal up for safekeeping.
The present invention takes the technology of the combination of Chinese and Western medicine, in the pharmaceutically-active situation of the original propofol of maintenance, improve analgesia function, and the comparatively serious cyclic inhibition effectively improved caused by propofol and respiration inhibition effect, decrease during use with the use of the consumption of analgesic, reduce drug side effect, improve clinical safety.
Although give some embodiments of the present invention, it will be understood by those of skill in the art that without departing from the spirit of the invention herein, can change embodiment herein.Above-described embodiment is exemplary, should using embodiment herein as the restriction of interest field of the present invention.
Claims (5)
1. an anesthetis, medicine based on propofol, with camomile extract, astragalus membranaceus powder, Mentholum, Radix Notoginseng powder and Flos Daturae extract for ancillary drug, is characterized in that, described component is counted with quality proportioning:
Propofol 85 ~ 90%;
Camomile extract 0.5% ~ 2.5%;
Astragalus membranaceus powder 1% ~ 3%;
Mentholum 0.5% ~ 1%;
Radix Notoginseng powder 1% ~ 3%;
Flos Daturae extract 4% ~ 8%.
2. a narcotic preparation method as claimed in claim 1, it is characterized in that, camomile extract, astragalus membranaceus powder, Mentholum, Radix Notoginseng powder and Flos Daturae extract is comprised the steps: to join respectively in propofol emulsion according to described formula dosage, at room temperature leave standstill after mixing and stirring, use vial to seal up for safekeeping.
3. narcotic preparation method as claimed in claim 2, is characterized in that, described room temperature is 20 ~ 25 DEG C, and described vial volume is 20mL.
4. a narcotic using method as claimed in claim 1, is characterized in that:
Described anesthetis can assist for spinal cord and epidural anesthesia and with conventional premedicant, neuromuscular blocking drug, inhalation anesthetic and analgesic with the use of;
Described anesthetis need dilute rear use, and with 5% glucose intravenous fluid dilution, dilution factor must not more than 1: 5;
Described anesthetis need use target control pump or micro pump to use through intravenous injection;
Described anesthetis adult dosage is 0.5 ~ 1.5mg/kg at induction period, and injection speed controls at 2mg/s, is 2 ~ 6mg/kg/h in maintenance phase;
Described anesthetis pediatric pharmaceuticals amount is 1.0 ~ 2.0mg/kg, and injection speed controls at 2mg/s, is 5 ~ 8mg/kg/h in maintenance phase.
5. narcotic using method as claimed in claim 4, is characterized in that, need with the use of low dose of analgesic when being used for general anesthesia without the need to analgesic with the use of, described anesthetis when described anesthetis is used for Little operation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510210042.2A CN104800396A (en) | 2015-04-29 | 2015-04-29 | Anesthetic and preparation method and use method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510210042.2A CN104800396A (en) | 2015-04-29 | 2015-04-29 | Anesthetic and preparation method and use method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104800396A true CN104800396A (en) | 2015-07-29 |
Family
ID=53685880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510210042.2A Pending CN104800396A (en) | 2015-04-29 | 2015-04-29 | Anesthetic and preparation method and use method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104800396A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106138530A (en) * | 2016-07-30 | 2016-11-23 | 李秀军 | A kind of surgery skin analgesia cream |
| CN110538222A (en) * | 2019-09-16 | 2019-12-06 | 肖颖 | compound anesthetic and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101287447A (en) * | 2005-08-12 | 2008-10-15 | 印度血清及疫苗有限公司 | Aqueous anaesthetic propofol composition comprising propofol |
| CN102973722A (en) * | 2012-11-28 | 2013-03-20 | 赵作君 | Novel anesthetic |
| CN103356609A (en) * | 2012-03-28 | 2013-10-23 | 陈希璇 | Compound intravenous anesthetic |
-
2015
- 2015-04-29 CN CN201510210042.2A patent/CN104800396A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101287447A (en) * | 2005-08-12 | 2008-10-15 | 印度血清及疫苗有限公司 | Aqueous anaesthetic propofol composition comprising propofol |
| CN103356609A (en) * | 2012-03-28 | 2013-10-23 | 陈希璇 | Compound intravenous anesthetic |
| CN102973722A (en) * | 2012-11-28 | 2013-03-20 | 赵作君 | Novel anesthetic |
Non-Patent Citations (1)
| Title |
|---|
| 宋晓乾: ""丙泊酚复合地佐辛或芬太尼用于无痛肠镜的临床效果"", 《临床麻醉学杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106138530A (en) * | 2016-07-30 | 2016-11-23 | 李秀军 | A kind of surgery skin analgesia cream |
| CN110538222A (en) * | 2019-09-16 | 2019-12-06 | 肖颖 | compound anesthetic and preparation method thereof |
| CN110538222B (en) * | 2019-09-16 | 2021-06-04 | 西安交通大学医学院第一附属医院 | Compound anesthetic and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dal et al. | A background infusion of morphine does not enhance postoperative analgesia after cardiac surgery | |
| BRPI0804623A2 (en) | use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive impairment | |
| Huang et al. | Inhalation of high concentration hydrogen gas improves short-term outcomes in a rat model of asphyxia induced-cardiac arrest | |
| CN104800396A (en) | Anesthetic and preparation method and use method thereof | |
| CN102641380B (en) | Traditional Chinese medicine compound preparation for treating rhinitis and nasosinusitis and preparation process thereof | |
| CN102973722B (en) | Novel anesthetic | |
| CN105311081A (en) | Application of Shanhaidan chrysanthemum indicum injection in aerosol inhalation, spray bottle aerial fog and rectal administration and method | |
| CN103837609B (en) | A kind of SHENGMAI ZHUSHEYE and preparation method thereof | |
| CN105287846A (en) | Application of Shanhaidan Yujin injection in atomizing inhalation, spray bottle aerosol and rectal administration and method | |
| CN103462942B (en) | A kind of suction ambroxol hydrochloride solution | |
| CN106138015A (en) | Propofol self-micro-emulsifying composition | |
| CN103263404B (en) | A kind of composite anaesthetic | |
| CN103142902B (en) | Traditional Chinese medicine composition and preparation for treating proliferative diseases of mammary gland as well as preparation method of traditional Chinese medicine composition | |
| CN103356609A (en) | Compound intravenous anesthetic | |
| CN104922620B (en) | Application and preparation method thereof of the mulberry leaf-ginger common cold injection in preparing atomization and rectally preparation | |
| CN109125410B (en) | Chinese herbal compound composition taking taxus chinensis as monarch drug and application thereof | |
| JP5764655B2 (en) | Pharmaceutical composition for treating drug addicts | |
| CN109172550A (en) | A kind of composite anaesthetic | |
| Wang et al. | Supervisory control of adverse reaction of traditional Chinese medicine injection | |
| McMurray et al. | A method for producing constant plasma concentrations of drugs: application to methohexitone | |
| CN103655524A (en) | Nose powder inhalation for treating epilepsy and preparation method thereof | |
| US20190015381A1 (en) | Cannabinoid Formulation and Products | |
| CN106668094A (en) | Nasal drop and preparation method thereof | |
| KR20120102214A (en) | A medicine for external application of natural and oriental herb complex | |
| Li et al. | Application of total intravenous anesthesia with remifentanyl and propofol to radiofrequency ablation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150729 |
|
| RJ01 | Rejection of invention patent application after publication |